论文部分内容阅读
目的:探索联合免疫策略对人乳头瘤病毒16型(HPV16)治疗疫苗L2E7E6和rAdE7E6的免疫效果的影响。方法:用L2E7E6融合蛋白和重组腺病毒rAd5E7E6以不同的联合免疫程序分别免疫C57BL/6小鼠,通过检测其诱发的体液免疫和细胞免疫反应,以及观察其在HPV16小鼠治疗模型中的抑瘤效果,比较分析联合免疫对小鼠免疫反应及治疗肿瘤效果的影响。结果:异源性联合免疫组均可检测到较高水平的体液免疫,该2组针对E6、E7特异性的T细胞免疫反应与同源性联合免疫2组相比明显提高,并在小鼠肿瘤治疗模型中能抑制肿瘤生长。结论:异源性联合免疫策略可明显提高HPV16 L2E7E6及rAd5E7E6疫苗的T细胞免疫反应,且有效治疗HPV16相关肿瘤,为HPV16L2E7E6及rAd5E7E6疫苗的应用提供了实验基础。
Objective: To explore the effect of combined immunization strategies on the immunological effects of HPV16 vaccine L2E7E6 and rAdE7E6. Methods: C57BL / 6 mice were immunized with L2E7E6 fusion protein and recombinant adenovirus rAd5E7E6 respectively, and their humoral and cellular immune responses were detected by immunocytochemistry. The anti-tumor activity of HPV16 mice Effect, a comparative analysis of the impact of combined immunization on immune response and treatment of tumor effect in mice. Results: The higher level of humoral immunity could be detected in allogeneic combined immunization group. The E6 and E7-specific T cell immune responses of the two groups were significantly increased compared with the two groups of homologous combined immunization, and in mice Tumor therapy models can inhibit tumor growth. Conclusion: Heterogeneous immunization strategy can significantly enhance the T cell immune response of HPV16 L2E7E6 and rAd5E7E6 vaccines and effectively treat HPV16-related tumors, providing the experimental basis for the application of HPV16L2E7E6 and rAd5E7E6 vaccines.